Akebia Therapeutics (AKBA) Long-Term Debt Repayments (2016 - 2025)
Historic Long-Term Debt Repayments for Akebia Therapeutics (AKBA) over the last 7 years, with Q1 2025 value amounting to $462000.0.
- Akebia Therapeutics' Long-Term Debt Repayments fell 9874.2% to $462000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $461000.0, marking a year-over-year decrease of 9897.78%. This contributed to the annual value of $37.1 million for FY2024, which is 1593.44% up from last year.
- Latest data reveals that Akebia Therapeutics reported Long-Term Debt Repayments of $462000.0 as of Q1 2025, which was down 9874.2% from -$1000.0 recorded in Q4 2024.
- Akebia Therapeutics' 5-year Long-Term Debt Repayments high stood at $36.7 million for Q1 2024, and its period low was -$1000.0 during Q4 2024.
- Its 4-year average for Long-Term Debt Repayments is $12.8 million, with a median of $8.0 million in 2023.
- Over the last 5 years, Akebia Therapeutics' Long-Term Debt Repayments had its largest YoY gain of 12953.75% in 2024, and its largest YoY loss of 10001.25% in 2024.
- Over the past 4 years, Akebia Therapeutics' Long-Term Debt Repayments (Quarter) stood at $33.0 million in 2022, then crashed by 75.76% to $8.0 million in 2023, then plummeted by 100.01% to -$1000.0 in 2024, then surged by 46300.0% to $462000.0 in 2025.
- Its last three reported values are $462000.0 in Q1 2025, -$1000.0 for Q4 2024, and $374000.0 during Q2 2024.